Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Empagliflozin |
| Synonyms | |
| Therapy Description |
Empagliflozin is an SLC5A2 (SGLT2) inhibitor, which potentially inhibits proliferation and migration and induces apoptosis of tumor cells and reduces tumor growth (PMID: 32931885). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Empagliflozin | BI-10773|BI10773|BI 10773 | Empagliflozin is an SLC5A2 (SGLT2) inhibitor, which potentially inhibits proliferation and migration and induces apoptosis of tumor cells and reduces tumor growth (PMID: 32931885). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|